Switzerland's Roche (ROG.S) has agreed to pay an initial $7.1 billion to Roivant (ROIV.O) and Pfizer (PFE.N) for rights to a new inflammatory bowel disease drug, as it expands into new fields to offset falling oncology sales.

Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.

Paige, a technology disruptor in healthcare, has joined forces with Microsoft in the fight against cancer, making headway in their collaboration to transform cancer diagnosis and patient care by building the world’s largest image-based artificial intelligence (AI) models for digital pathology and oncology.

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2023.

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment.

Global life sciences company Labcorp has introduced a new liquid biopsy test called Labcorp Plasma Focus.

Berry Genomics recently announced that it will acquire NeoGenomics, a US-based blood testing company, for US$2.4 billion to further strengthen its oncology testing business.